24 research outputs found
The Vortex-Wave equation with a single vortex as the limit of the Euler equation
In this article we consider the physical justification of the Vortex-Wave
equation introduced by Marchioro and Pulvirenti in the case of a single point
vortex moving in an ambient vorticity. We consider a sequence of solutions for
the Euler equation in the plane corresponding to initial data consisting of an
ambient vorticity in and a sequence of concentrated blobs
which approach the Dirac distribution. We introduce a notion of a weak solution
of the Vortex-Wave equation in terms of velocity (or primitive variables) and
then show, for a subsequence of the blobs, the solutions of the Euler equation
converge in velocity to a weak solution of the Vortex-Wave equation.Comment: 24 pages, to appea
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer : final results of a randomized European Organization for Research and Treatment of Cancer study
Contains fulltext :
22503___.PDF (publisher's version ) (Open Access
120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer
Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU). Objective response was demonstrated in 19 patients (52.7%), stable disease in 7 patients (19.4%) and progression of the disease in 10 patients (27.7%). Similar response rate was observed according to tumor site (soft tissues, 50%; bone, 52%; lung, 63%; liver, 55%; and pleura and peritoneum, 42%) and previous treatment (previous chemotherapy, 48%; previously untreated, 61%). Median duration of response was 8 months. Toxicity was characterized by stomatitis and myelodepression and required dose adjustments in 30% of patients. CDDP and 5-FU infusion deserve further investigation because it appeared to have substantial activity in this preliminary study in metastatic breast cancer
120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer
Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU). Objective response was demonstrated in 19 patients (52.7%), stable disease in 7 patients (19.4%) and progression of the disease in 10 patients (27.7%). Similar response rate was observed according to tumor site (soft tissues, 50%; bone, 52%; lung, 63%; liver, 55%; and pleura and peritoneum, 42%) and previous treatment (previous chemotherapy, 48%; previously untreated, 61%). Median duration of response was 8 months. Toxicity was characterized by stomatitis and myelodepression and required dose adjustments in 30% of patients. CDDP and 5-FU infusion deserve further investigation because it appeared to have substantial activity in this preliminary study in metastatic breast cancer
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Contains fulltext :
89523.pdf (publisher's version ) (Open Access)BACKGROUND: Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer. METHODS: We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based chemotherapy followed by debulking surgery (so-called interval debulking surgery). RESULTS: Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment. The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest residual tumor was 1 cm or less in diameter in 41.6% of patients after primary debulking and in 80.6% of patients after interval debulking. Postoperative rates of adverse effects and mortality tended to be higher after primary debulking than after interval debulking. The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P=0.01 for noninferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15). Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival. CONCLUSIONS: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003636.
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
BACKGROUND. Although the value of primary cytoreductive surgery for
epithelial ovarian cancer is beyond doubt, the value of debulking surgery
after induction chemotherapy has not yet been defined. In this randomized
study we investigated the effect on survival of debulking surgery.
METHODS. Eligible patients had residual lesions measuring more than 1 cm
in diameter after primary surgery. After three cycles of cyclophosphamide
and cisplatin, these patients were randomly assigned to undergo either
debulking surgery or no surgery, followed by further cycles of
cyclophosphamide and cisplatin. The study end points were progression-free
and overall survival. At surgery 65 percent of the patients had lesions
measuring more than 1 cm. In 45 percent of this group, the lesions were
reduced surgically to less than 1 cm. RESULTS. Of the 319 patients who
underwent randomization, 278 could be evaluated (140 patients who
underwent surgery and 138 patients who did not). Progression-free and
overall survival were both significantly longer in the group that
underwent surgery (P = 0.01). The difference in median survival was six
months. The survival rate at two years was 56 percent for the group that
underwent surgery and 46 percent for the group that did not. In the
multivariate analysis, debulking surgery was an independent prognostic
factor (P = 0.012). Overall, after adjustment for all other prognostic
factors, surgery reduced the risk of death by 33 percent (95 percent
confidence interval, 10 to 50 percent; P = 0.008). Surgery was not
associated with death or severe morbidity. CONCLUSIONS: Debulking surgery
significantly lengthened progression-free and overall survival. The risk
of death was reduced by one third, after adjustment for a variety of
prognostic factors